Tarsus Pharmaceuticals (TARS) Change in Receivables (2021 - 2026)

Tarsus Pharmaceuticals' Change in Receivables history runs 6 years deep, the most recent figure standing at $30.3 million for Q1 2026.

• On a quarterly basis, Change in Receivables rose 93.33% year-over-year to $30.3 million in Q1 2026; TTM through Mar 2026 was $52.9 million, a 62.62% increase from a year earlier, with the FY2025 full-year figure at $38.3 million, up 27.07% from the prior year.
• Change in Receivables advanced to $30.3 million in Q1 2026 per TARS's latest filing, from $12.4 million in the prior quarter.
• Across five years, Change in Receivables topped out at $30.3 million in Q1 2026 and bottomed at -$4.1 million in Q2 2025.
• The 5-year median for Change in Receivables is $5.4 million (2023), against an average of $7.7 million.
• Across the five-year window, Change in Receivables jumped 66329.41% in 2023 and sank 1049.44% in 2025, its largest moves.
• Year by year, Change in Receivables stood at -$17000.0 in 2022, then soared by 66329.41% to $11.3 million in 2023, then jumped by 56.33% to $17.6 million in 2024, then decreased by 29.34% to $12.4 million in 2025, then surged by 143.52% to $30.3 million in 2026.
• Per Business Quant, the three latest TARS Change in Receivables figures stand at $30.3 million (Q1 2026), $12.4 million (Q4 2025), and $14.3 million (Q3 2025).